Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells
Open accessAbstract
Key Points: Crosspriming of AAV capsid-specific CD8+ T cells requires cooperation between distinct subsets of DCs. Innate immune sensing of the viral DNA genome induces cross-presentation of viral capsid in trans.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The AAV vector genome triggers TLR9, a receptor that detects foreign DNA.
“the genome of the vector activates Toll-like receptor 9 (TLR9), a pattern recognition receptor that senses foreign DNA”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [18]
pDCs are critical for the early TLR9/MyD88-dependent innate response to AAV and orchestrate anti-capsid CD8+ T cell responses by activating conventional DCs to cross-present capsid antigen.
“Plasmacytoid dendritic cells (pDCs) are critical for mounting a TLR9/MyD88-dependent early innate immune response to AAV vectors (15) and they subsequently orchestrate anti-capsid CD8+ T cell responses in vivo by activating conventional DCs to cross-present capsid antigen (18).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [18]
The TLR9/MyD88 pathway is vital for mounting a CD8+ T-cell response against the AAV capsid and also liver and muscle-directed transgenes.
“Furthermore, the TLR9/MyD88 pathway is not only vital for mounting a CD8+ T-cell response against the AAV capsid but also liver and muscle-directed transgenes [28, 34, 35, 41].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [28]
Adaptive anti-capsid humoral and cytotoxic immune responses have been shown to be restricted in vivo by inhibiting innate immune activation pathways.
“Adaptive anti-capsid humoral [27] and cytotoxic [28, 29] immune responses have been shown to be restricted in vivo by inhibiting innate immune activation pathways.”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [28]
Cooperation between plasmacytoid dendritic cells, conventional dendritic cells, and CD4+ T cells results in cross-presentation of AAV particles on MHC I, and subsequently activation of CD8+ T cells.
“Studies suggest that cooperation between plasmacytoid DCs, conventional DCs, and CD4+ T cells results in cross-presentation of AAV particles on MHC I, and, subsequently, activation of CD8+ T cells [28, 29].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [28]
Capsid-specific CD8+ T cells expand and potentially clear AAV transduced cells, which results in loss of transgene expression and inflammation of target organs.
“Capsid-specific CD8+ T cells expand and potentially clear AAV transduced cells, which results in loss of transgene expression and inflammation of target organs [59, 60].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [60]
pDCs do not participate directly in CD8+ T cell priming.
“but did not participate directly in CD8+ T cell priming (42).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [42]
In mice, cDCs play a role in priming of a cytotoxic T cell response against immunogenic ovalbumin peptide inserted into the AAV2 capsid protein sequence.
“In mice, cDCs were shown to play a role in priming of a cytotoxic T cell response against immunogenic ovalbumin peptide inserted into the AAV2 capsid protein sequence (42).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [42]
More recent work has highlighted the role of the innate immune system in response to AAV therapeutics.
“More recent work has highlighted the role of innate immune system in response to AAV therapeutics (42–46)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [42]
Both TLR9 and T1 IFNs, and also CD4+ T help, are requisite for anti-capsid CD8+ T cell priming.
“Indeed, both TLR9 and T1 IFNs (and also CD4+ T help) are requisite for anti-capsid CD8+ T cell priming (9, 15).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [9]
TLR9 sensing of AAV vector genomes is required for anti-capsid CD8+ T cell responses.
“Importantly, TLR9 sensing of AAV vector genomes has been shown to be required for anti-capsid CD8+ T cell responses (9–14).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [9]
Type 1 IFN together with CD4+ T cell help contributes to licensing of cDCs, which then prime capsid-specific CD8+ T cells.
“T1 IFN along with CD4+ T cell help contributes to licensing of cDCs, which then prime capsid specific CD8+ T cells (9, 15).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [9]
CpG depletion does not eliminate antibody formation against the capsid or the transgene product, which can be modified by but does not depend on the TLR9-MyD88 pathway.
“Another limitation is that CpG depletion does not eliminate antibody formation against the capsid or transgene product, which can be modified by but does not depend on the TLR9-MyD88 pathway (9, 12, 15).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [9]
Even TLR9-deficient mice do not show complete abolishment of CD8+ T cell responses.
“However, it should be pointed out that even TLR9 deficient mice do not show complete abolishment of CD8+ T cell responses, as our current and published studies have shown (7–9).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [9]
Adaptive immune responses to AAV capsid were independent of TLR2 in a murine model of muscle gene transfer.
“However, adaptive immune responses to the capsid were found to be independent of TLR2 in a murine model of muscle gene transfer.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [26]
A strong dependency of immune responses to AAV gene transfer on TLR2 has not been documented.
“Thus far, a strong dependency of immune responses to AAV gene transfer on TLR2 has not been documented.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [26]
Several other studies showed no effect of STING deficiency on B or T cell responses.
“Several other studies showed no effect of STING deficiency on B or T cell responses.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [26]
Sensing of the AAV genome by TLR9 in pDCs conditions conventional cross-presenting dendritic cells (cDCs) via IFN-I to prime AAV capsid-specific CD8+ T cells.
“Sensing of the AAV genome by TLR9 in plasmacytoid dendritic cells (pDCs) conditions conventional cross-presenting dendritic cells (cDCs) via IFN-I to prime AAV capsid-specific CD8+ T cells.17,24,25,26”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
Despite evidence for various innate responses to AAV, the existence of other pathways leading to antigen-specific T cell responses has been unknown.
“Despite evidence for various innate responses to AAV, the existence of other pathways leading to antigen-specific T cell responses has been unknown.24,25,43,44,45”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
The requirements for presentation to transgene product-specific CD8+ T cells are similar to those for MHC class I presentation of AAV capsid antigen.
“In this regard, the requirements are similar to those for MHC class I presentation of AAV capsid antigen.25,41”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
In lymphoid organs, anti-viral responses may be orchestrated by migration of pDCs and XCR1+ DCs to sites of virally infected APCs, where they co-cluster, allowing pDCs to condition XCR1+ DCs through IFN-I.
“In lymphoid organs, anti-viral responses may be orchestrated by migration of pDCs and XCR1+ DCs to sites of virally infected APCs, where they co-cluster, allowing pDCs to condition XCR1+ DCs through IFN-I.25,26”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
CD8+ T cell responses against input capsid may develop faster in mice than against the transgene product.
“CD8+ T cell responses against input capsid may develop faster in mice than against the transgene product.25,65”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
XCR1+ cDCs closely cooperate with pDCs in cross-priming of CD8+ T cells, with pDCs conditioning the XCR1+ cDCs with cytokines.
“XCR1+ cDCs closely cooperate with pDCs in cross-priming of CD8+ T cells, with pDCs conditioning the XCR1+ cDCs with cytokines.25,26,35”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
AAV8 does not elicit a CD8+ T cell response against capsid in mice, and the vector dose was too low to generate such a response.
“However, this does not apply here because AAV8 does not elicit a CD8+ T cell response against capsid in mice and because the vector dose was anyhow too low to generate such a response.25,66,67”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
Cross-priming of anti-viral CD8+ T cell responses following TLR9 activation in pDCs requires IFNAR expression in cDCs.
“Cross-priming of anti-viral CD8+ T cell responses following TLR9 activation in pDCs requires IFNAR expression in cDCs.25”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [25]
TLR9 recognizes unmethylated CpG sequences present in viral or bacterial but not mammalian DNA and is the sensor involved in the induction of type I IFN responses in pDCs.
“Previous work had identified TLR9, which recognizes unmethylated CpG sequences present in viral or bacterial but not mammalian DNA, as the sensor involved in the induction of type I IFN responses in pDCs 20,22 .”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [20]
All of the AAV-induced cytokines and chemokines can be upregulated by activation of TLR9 in the periphery using synthetic CpG-rich oligonucleotides.
“all of the AAV-induced cytokines and chemokines can be upregulated by activation of TLR9 in the periphery using synthetic CpG-rich oligonucleotides.8,9,10,11,12,52,53,54,55,56,57,58”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Jayandharan, G. R., Aslanidi, G., Martino, A. T., Jahn, S. C., Perrin, G. Q., Herzog, R. W., & Srivastava, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012753108 · Cited by 72 · see citing works
Self-citationRetractedToll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658 · see citing works
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · see citing works
Jung, S., Unutmaz, D., Wong, P., Sano, G., Santos, K. D. L., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,953 · see citing works
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · see citing works
Self-citationLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273 · see citing works
Self-citationTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · see citing works
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · see citing works
Self-citationBennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461 · see citing works
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404 · see citing works
Zhu, J., Huang, X., & Yang, Y. (2007) · Journal of Virology · doi:10.1128/jvi.02192-06 · Cited by 370 · see citing works
Bifurcation of Toll-Like Receptor 9 Signaling by Adaptor Protein 3
Sasai, M., Linehan, M. M., & Iwasaki, A. (2010) · Science · doi:10.1126/science.1187029 · Cited by 357 · see citing works
Fonteneau, J., Larsson, M., Beignon, A., McKenna, K., DaSilva, I., Amara, A., Liu, Y.-J., Lifson, J. D., Littman, D. R., & Bhardwaj, N. (2004) · Journal of Virology · doi:10.1128/jvi.78.10.5223-5232.2004 · Cited by 351 · see citing works
Brewitz, A., Eickhoff, S., Dähling, S., Quast, T., Bedoui, S., Kroczek, R. A., Kurts, C., Garbi, N., Barchet, W., Iannacone, M., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.01.003 · Cited by 339 · see citing works
Zhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330 · see citing works
Nair-Gupta, P., Baccarini, A., Tung, N., Seyffer, F., Florey, O., Huang, Y., Banerjee, M., Overholtzer, M., Roche, P. A., Tampé, R., et al. (2014) · Cell · doi:10.1016/j.cell.2014.04.054 · Cited by 327 · see citing works
Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327 · see citing works
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295 · see citing works
Self-citationCpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254 · see citing works
Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246 · see citing works
Self-citationDendritic cell maturation and cross‐presentation: timing matters!
Alloatti, A., Kotsias, F., Magalhaes, J. G., & Amigorena, S. (2016) · Immunological Reviews · doi:10.1111/imr.12432 · Cited by 244 · see citing works
Zhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232 · see citing works
Self-citationHösel, M., Broxtermann, M., Janicki, H., Esser, K., Arzberger, S., Hartmann, P., Gillen, S., Kleeff, J., Stabenow, D., Odenthal, M., et al. (2012) · Hepatology · doi:10.1002/hep.24625 · Cited by 219 · see citing works
Pantel, A. R., Teixeira, A., Haddad, E. K., Wood, E. G., Steinman, R. M., & Longhi, M. P. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001759 · Cited by 210 · see citing works
Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides
Mutwiri, G., Nichani, A., Babiuk, S., & Babiuk, L. A. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.022 · Cited by 207 · see citing works
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192 · see citing works
Self-citationType 1 Interferons and Antiviral CD8 T-Cell Responses
Welsh, R. M., Bahl, K., Marshall, H. D., & Urban, S. L. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002352 · Cited by 189 · see citing works
Innate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178 · see citing works
Self-citationMueller, C., Chulay, J. D., Trapnell, B. C., Humphries, M., Carey, B., Sandhaus, R. A., McElvaney, N. G., Messina, L., Tang, Q., Rouhani, F. N., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70314 · Cited by 169 · see citing works
Martino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162 · see citing works
Self-citationRegulation of B‐cell responses by Toll‐like receptors
Browne, E. (2012) · Immunology · doi:10.1111/j.1365-2567.2012.03587.x · Cited by 150 · see citing works
Spadaro, F., Lapenta, C., Donati, S., Abalsamo, L., Barnaba, V., Belardelli, F., Santini, S. M., & Ferrantini, M. (2011) · Blood · doi:10.1182/blood-2011-06-363564 · Cited by 150 · see citing works
Kuwajima, S., Sato, T., Ishida, K., Tada, H., Tezuka, H., & Ohteki, T. (2006) · Nature Immunology · doi:10.1038/ni1348 · Cited by 148 · see citing works
Li, Z., Zhao, W., Wu, J., Li, B., Zolotukhin, S., Lakshmanan Govindasamy, A., Agbandje‐McKenna, M., & Srivastava, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300170 · Cited by 146 · see citing works
Self-citationB-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Corti, M., Elder, M., Falk, D., Lawson, L., Smith, B., Nayak, S., Conlon, T., Clément, N., Erger, K., Lavassani, E., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.33 · Cited by 140 · see citing works
Self-citationStahnke, S., Lux, K., Uhrig, S., Kreppel, F., Hösel, M., Coutelle, O., Ogris, M., Hallek, M. J., & Büning, H. (2010) · Virology · doi:10.1016/j.virol.2010.09.025 · Cited by 126 · see citing works
Finn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115 · see citing works
Recognition of cytosolic DNA by c GAS and other STING ‐dependent sensors
Bhat, N., & Fitzgerald, K. A. (2013) · European Journal of Immunology · doi:10.1002/eji.201344127 · Cited by 113 · see citing works
Wang, L., Figueredo, J., Calcedo, R., Lin, J., & Wilson, J. M. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.001 · Cited by 113 · see citing works
Pinto, A. K., Daffis, S., Brien, J. D., Gainey, M. D., Yokoyama, W. M., Sheehan, K. C. F., MURPHY, K. M. M., Schreiber, R. D., & Diamond, M. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002407 · Cited by 107 · see citing works
Suárez‐Fariñas, M., Arbeit, R. D., Jiang, W., Ortenzio, F. S., Sullivan, T., & Krueger, J. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084634 · Cited by 95 · see citing works
Ertl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94 · see citing works
Rogers, G. L., Suzuki, M., Zolotukhin, I., Markusic, D. M., Morel, L. M., Lee, B., Ertl, H. C. J., & Herzog, R. W. (2015) · Journal of Innate Immunity · doi:10.1159/000369273 · Cited by 85 · see citing works
Self-citationKumar, S. R. P., Hoffman, B. E., Terhorst, C., de Jong, Y. P., & Herzog, R. W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.014 · Cited by 83 · see citing works
Self-citationPiccioli, D., Sammicheli, C., Tavarini, S., Nuti, S., Frigimelica, E., Manetti, A. G. O., Nuccitelli, A., Aprea, S., Valentini, S. B., Borgogni, E., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186890 · Cited by 83 · see citing works
Intracellular recycling and cross‐presentation by MHC class I molecules
Endert, P. V. (2016) · Immunological Reviews · doi:10.1111/imr.12424 · Cited by 80 · see citing works
Sack, B. K., Merchant, S. N., Markusic, D. M., Nathwani, A. C., Davidoff, A. M., Byrne, B. J., & Herzog, R. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037671 · Cited by 75 · see citing works
Self-citationBiswas, M., Sarkar, D., Kumar, S. R. P., Nayak, S., Rogers, G. L., Markusic, D. M., Liao, G., Terhorst, C., & Herzog, R. W. (2015) · Blood · doi:10.1182/blood-2014-09-599266 · Cited by 70 · see citing works
Self-citationAdeno-associated virus capsid antigen presentation is dependent on endosomal escape
Li, C., He, Y., Nicolson, S., Hirsch, M., Weinberg, M. S., Zhang, P., Kafri, T., & Samulski, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66611 · Cited by 61 · see citing works
Parvoviruses: Structure and Infection
Halder, S., Ng, R., & Agbandje‐McKenna, M. (2012) · Future Virology · doi:10.2217/fvl.12.12 · Cited by 53 · see citing works
Targeted approaches to induce immune tolerance for Pompe disease therapy
Doerfler, P. A., Nayak, S., Corti, M., Morel, L. M., Herzog, R. W., & Byrne, B. J. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.53 · Cited by 51 · see citing works
Self-citationAgudo, J., Ruzo, A., Kitur, K., Sachidanandam, R., Blander, J. M., & Brown, B. D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.150 · Cited by 48 · see citing works
Pre‐Clinical Safety Evaluation of Pyrrolidine Dithiocarbamate
Chabicovsky, M., Prieschl‐Grassauer, E., Seipelt, J., Muster, T., Szolar, O. H. J., Hebar, A., & Doblhoff‐Dier, O. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00573.x · Cited by 48 · see citing works
Rossetti, M. M., Gregori, S., Hauben, E., Brown, B. D., Sergi, L. S., Naldini, L., & Roncarolo, M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.085 · Cited by 47 · see citing works
Rogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-25 · Cited by 45 · see citing works
Self-citationPerrin, G. Q., Zolotukhin, I., Sherman, A., Biswas, M., de Jong, Y. P., Terhorst, C., Davidoff, A. M., & Herzog, R. W. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.83 · Cited by 40 · see citing works
Self-citationWu, T.-L., Li, H., Faust, S. M., Chi, E., Zhou, S., Wright, F., High, K. A., & Ertl, H. C. (2014) · Molecular Therapy · doi:10.1038/mt.2013.218 · Cited by 38 · see citing works
Hemophilia Gene Therapy: Caught Between a Cure and an Immune Response
Herzog, R. W. (2015) · Molecular Therapy · doi:10.1038/mt.2015.135 · Cited by 35 · see citing works
Self-citationBakdash, G., Schreurs, I., Schreibelt, G., & Tel, J. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.912561 · Cited by 27 · see citing works
de Ruiter, P. E., Boor, P. P. C., de Jonge, J., Metselaar, H. J., Tilanus, H. W., IJzermans, J. N. M., Kwekkeboom, J., & van der Laan, L. J. W. (2015) · Transplant Infectious Disease · doi:10.1111/tid.12430 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788 · see citing works
Self-citationPlasmacytoid Dendritic Cells: Development, Regulation, and Function
Reizis, B. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.027 · Cited by 679 · see citing works
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641 · see citing works
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Fu, C., & Jiang, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03059 · Cited by 602 · see citing works
Detection of Viral Infections by Innate Immunity
Carty, M., Guy, C., & Bowie, A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114316 · Cited by 406 · see citing works
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357 · see citing works
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 361 · see citing works
Peña-Romero, A. C., & Orenes‐Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 262 · see citing works
Unraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234 · see citing works
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212 · see citing works
Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215 · see citing works
“Engineered AAV2 vector diminishes inflammatory and innate immune responses in primary human plasmacytoid and monocyte-derived dendritic cells Plasmacytoid dendritic cells (pDCs) are critical for mounting a TLR9/MyD88-dependent early innate immune response to AAV vectors (15), and they subsequently orchestrate anti-cap…”
BackgroundRegulation of the Cell Biology of Antigen Cross-Presentation
Blander, J. M. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055523 · Cited by 193 · see citing works
Update on clinical gene therapy for hemophilia
Perrin, G. Q., Herzog, R. W., & Markusic, D. M. (2018) · Blood · doi:10.1182/blood-2018-07-820720 · Cited by 183 · see citing works
Self-citationAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174 · see citing works
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159 · see citing works
“Capsid-specific CD8+ T cells expand and potentially clear AAV transduced cells, which results in loss of transgene expression and inflammation of target organs [59, 60].”
BackgroundDC-Based Vaccines for Cancer Immunotherapy
Fu, C., Zhou, L., Mi, Q., & Jiang, A. (2020) · Vaccines · doi:10.3390/vaccines8040706 · Cited by 147 · see citing works
Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines
Sartorius, R., Trovato, M., Manco, R., D’Apice, L., & Berardinis, P. D. (2021) · npj Vaccines · doi:10.1038/s41541-021-00391-8 · Cited by 132 · see citing works
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131 · see citing works
Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity
Noubade, R., Majri-Morrison, S. S., & Tarbell, K. V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01014 · Cited by 130 · see citing works
Xiao, W., Chan, A. C. L., Waarts, M. R., Mishra, T., Liu, Y., Cai, S. F., Yao, J., Gao, Q., Bowman, R. L., Koche, R. P., et al. (2020) · Blood · doi:10.1182/blood.2020007897 · Cited by 125 · see citing works
Mendell, J. R., Connolly, A. M., Lehman, K. J., Griffin, D. A., Khan, S. Z., Dharia, S. D., Quintana-Gallardo, L., & Rodino-Klapac, L. R. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.011 · Cited by 124 · see citing works
Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Hamilton, B. A., & Wright, J. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675897 · Cited by 118 · see citing works
Fu, C., Peng, P., Loschko, J., Li, F., Pham, P., Cui, W., Lee, K. P., Krug, A., & Jiang, A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002345117 · Cited by 116 · see citing works
Exposure to wild-type AAV drives distinct capsid immunity profiles in humans
Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104 · see citing works
Immune Response Mechanisms against AAV Vectors in Animal Models
Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97 · see citing works
Pipe, S. W., Leebeek, F. W. G., Ferreira, V., Sawyer, E. K., & Pasi, J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.015 · Cited by 92 · see citing works
T Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88 · see citing works
Rossi, A., Dupaty, L., Aillot, L., Zhang, L., Gallien, C., Hallek, M., Odenthal, M., Adriouch, S., Salvetti, A., & Büning, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-40071-1 · Cited by 85 · see citing works
Smith, C. J., Ross, N., Kamal, A., Kim, K. Y., Kropf, E., Deschatelets, P., Francois, C., Quinn, W. J., Singh, I., Majowicz, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999021 · Cited by 86 · see citing works
“A different type of dendritic cells, pDCs, was shown to secrete type I interferons in response to AAV (49), but did not participate directly in CD8 T cell priming (42).”
BackgroundMonahan, P. E., Négrier, C., Tarantino, M. D., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85 · see citing works
Prasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81 · see citing works
Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy
Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80 · see citing works
“AAV-capsid specific CD8 T cells in peripheral blood were quantitated over time by flow cytometry using an H-2Kb SIINFEKL tetramer (9).”
BackgroundMethodInfluentialSelf-citationShirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79 · see citing works
Self-citationChowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 78 · see citing works
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 70 · see citing works
Mücke, M. M., Fong, S., Foster, G. R., Lillicrap, D., Miesbach, W., & Zeuzem, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.029 · Cited by 71 · see citing works
The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer
Xiang, Z., Kurupati, R. K., Li, Y., Kuranda, K., Zhou, X., Mingozzi, F., High, K. A., & Ertl, H. C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.014 · Cited by 67 · see citing works
TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy
Ashley, S. N., Somanathan, S., Giles, A. R., & Wilson, J. M. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103997 · Cited by 67 · see citing works
Codon-optimization in gene therapy: promises, prospects and challenges
Paremskaia, A. I., Kogan, A. A., Murashkina, A., Naumova, D. A., Satish, A., Abramov, I. S., Feoktistova, S. G., Mityaeva, O. N., Deviatkin, A. A., & Volchkov, P. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1371596 · Cited by 66 · see citing works
Assessment of Humoral, Innate, and T-Cell Immune Responses to Adeno-Associated Virus Vectors
Calcedo, R., Chichester, J. A., & Wilson, J. M. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.038 · Cited by 62 · see citing works
Hemophilia gene therapy comes of age
George, L. A. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009878 · Cited by 62 · see citing works
Brown, D. A., Altermatt, M., Dobreva, T., Chen, S., Wang, A. Z., Thomson, M. W., & Gradinaru, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730825 · Cited by 58 · see citing works
Plasmacytoid Dendritic Cells and Cancer Immunotherapy
Fu, C., Zhou, L., Mi, Q., & Jiang, A. (2022) · Cells · doi:10.3390/cells11020222 · Cited by 61 · see citing works
Hemophilia gene therapy comes of age
George, L. A. (2017) · Hematology · doi:10.1182/asheducation-2017.1.587 · Cited by 58 · see citing works
Humoral immune responses to <scp>AAV</scp> gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52 · see citing works
Muhuri, M., Zhan, W., Maeda, Y., Li, J., Lotun, A., Chen, J., Sylvia, K., Dasgupta, I., Arjomandnejad, M., Nixon, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674242 · Cited by 50 · see citing works
Innate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50 · see citing works
Self-citationDendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities
Fu, C., Ma, T., Zhou, L., Mi, Q., & Jiang, A. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2109486 · Cited by 50 · see citing works
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 46 · see citing works
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41 · see citing works
Self-citationUnderstanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 40 · see citing works
AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
Palaschak, B., Herzog, R. W., & Markusic, D. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_20 · Cited by 37 · see citing works
Self-citationGene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Herzog, R. W., Kaczmarek, R., & High, K. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.043 · Cited by 37 · see citing works
Self-citationEmerging therapies for hemophilia: controversies and unanswered questions
Arruda, V. R., Doshi, B. S., & Samelson‐Jones, B. J. (2018) · F1000Research · doi:10.12688/f1000research.12491.1 · Cited by 36 · see citing works
Current and innovative emerging therapies for porphyrias with hepatic involvement
Fontanellas, A., Avila, M. A., Anderson, K. E., & Deybach, J. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.003 · Cited by 36 · see citing works
Butterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35 · see citing works
Self-citationKachanov, A., Kostyusheva, A., Brezgin, S., Karandashov, I., Ponomareva, N. I., Tikhonov, A., Lukashev, A. N., Pokrovsky, V. S., Zamyatnin, A. A., Parodi, A., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22036 · Cited by 38 · see citing works
Modifying immune responses to adeno-associated virus vectors by capsid engineering
Bentler, M., Hardet, R., Ertelt, M., Rudolf, D., Kaniowska, D., Schneider, A., Vondran, F. W. R., Schoeder, C. T., Delphin, M., Lucifora, J., et al. (2023) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.015 · Cited by 34 · see citing works
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33 · see citing works
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 33 · see citing works
Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Abou Alezz, M., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58778-3 · Cited by 32 · see citing works
Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy
Jagadisan, B., & Dhawan, A. K. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00624-5 · Cited by 31 · see citing works
TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
Kumar, S. R. P., Biswas, M., Cao, D., Arisa, S., Muñoz-Melero, M., Lam, A. K., Piñeros, A. R., Kapur, R., Kaisho, T., Kaufman, R. J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.029 · Cited by 31 · see citing works
Self-citationImmune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28 · see citing works
Self-citationImpact of liver fibrosis on AAV-mediated gene transfer to mouse hepatocytes
Ferriero, R., Bruno, G., Padula, A., Pisano, S., Boffa, I., Gargaro, M., Imperatore, T., Battipaglia, M., Vivenzio, S., Perna, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57382-9 · Cited by 24 · see citing works
Suriano, C. M., Kumar, N., Verpeut, J. L., Ma, J., Jung, C., Dunn, C. E., Carvajal, B. V., Nguyen, A. V., & Boulanger, L. M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.036 · Cited by 21 · see citing works
Retina-directed gene therapy: Achievements and remaining challenges
Biber, J., Gandor, C. L. A., Bećirović, E., & Michalakis, S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108862 · Cited by 24 · see citing works
Longo, M., Paolini, E., Meroni, M., & Dongiovanni, P. (2022) · Biomedicines · doi:10.3390/biomedicines10030648 · Cited by 20 · see citing works
Preclinical models to assess the immunogenicity of AAV vectors
Ertl, H. C. J. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.11.006 · Cited by 20 · see citing works
Kaczmarek, R., Piñeros, A. R., Patterson, P. E., Bertolini, T. B., Perrin, G. Q., Sherman, A., Born, J., Arisa, S., Arvin, M. C., Kamocka, M. M., et al. (2023) · Blood · doi:10.1182/blood.2022018937 · Cited by 19 · see citing works
Self-citationCapsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy
Franke, A., Hardet, R., Prager, L., Bentler, M., Demeules, M., John-Neek, P., Jäschke, N. M., Ha, T. C., Hacker, U. T., Adriouch, S., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.03.010 · Cited by 18 · see citing works
Ultrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice
Song, S., Lyle, M. J., Noble-Vranish, M. L., Tran, D. M., Harrang, J., Xiao, W., Unger, E. C., & Miao, C. H. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.006 · Cited by 17 · see citing works
Adeno-associated virus (AAV) reduces cortical dendritic complexity in a TLR9-dependent mannerPreprint
Suriano, C. M., Verpeut, J. L., Kumar, N., Ma, J., Jung, C., & Boulanger, L. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.28.462148 · Cited by 17 · see citing works
Kumar, S. R. P., Xie, J., Hu, S., Ko, J., Huang, Q., Brown, H. C., Srivastava, A., Markusic, D. M., Doering, C. B., Spencer, H. T., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.08.001 · Cited by 16 · see citing works
Self-citationLi, Z., Zhuang, H., Chen, X., Zhang, Y., Ma, Z., Wang, S., Yan, Q., Zhou, Z., Huang, S., Zhang, C., et al. (2022) · Journal of Oncology · doi:10.1155/2022/4269733 · Cited by 15 · see citing works
Xicluna, R., Schwalie, P. C., Bell, E., von Tell, D., Steiner, G., Seeger, E., Heeren, J. J. F., Turksma, A. W., Pouw, R. B., Schwandt, T., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101551 · Cited by 14 · see citing works
Current and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy
Piccolo, P., & Brunetti‐Pierri, N. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.179 · Cited by 14 · see citing works
Gene therapy – are we ready now?
Kaczmarek, R. (2022) · Haemophilia · doi:10.1111/hae.14530 · Cited by 13 · see citing works
Duan, D., & Herzog, R. W. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.067 · Cited by 16 · see citing works
Self-citationKistner, A., Chichester, J. A., Wang, L., Calcedo, R., Greig, J. A., Cardwell, L. N., Wright, M. C., Couthouis, J., Sethi, S., McIntosh, B. E., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00423-z · Cited by 13 · see citing works
Redundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer
Li, N., Kumar, S. R. P., Cao, D., Muñoz-Melero, M., Arisa, S., Brian, B. A., Greenwood, C. M., Yamada, K., Duan, D., & Herzog, R. W. (2024) · Viruses · doi:10.3390/v16101507 · Cited by 14 · see citing works
Self-citationGaillard, J. R., Gu, A. R., & Knierbein, E. E. N. (2023) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2023.113493 · Cited by 13 · see citing works
Muñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 13 · see citing works
Self-citationWang, J., Zhao, P., Chen, Z., Wang, H., Wang, Y., & Lin, Q. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100632 · Cited by 11 · see citing works
Alakhras, N. S., Moreland, C. A., Wong, L. C., Raut, P., Kamalakaran, S., Wen, Y., Siegel, R. W., & Malherbe, L. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1354055 · Cited by 10 · see citing works
Pan, T. S., Yang, C.-H., Zhao, K., Sun, Y.-L., Rao, Z., Qu, W., Zhang, S., Jin, X., Yu, Y., & Zhang, X. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100143 · Cited by 9 · see citing works
Molina, E., Tejero, M., Duzenli, O. F., Kuoch, H., Caine, C., Krotova, K. Y., Paulaitis, M. E., & Aslanidi, G. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101358 · Cited by 7 · see citing works
Seitz, I. P., Rodríguez‐Bocanegra, E., Bucher, K., Reichel, F. F., Michalakis, S., Romanovsky, D., Biel, M., Wissinger, B., Bartz‐Schmidt, K. U., Peters, T. M., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.6.38 · Cited by 7 · see citing works
Araujo, A. E., Bentler, M., Garmendia, X. P., Kaleem, A., Fabian, C., Morgan, M. A., Hacker, U. T., & Büning, H. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.114 · Cited by 7 · see citing works
Effector Functions of Dendritic Cells in Cancer: Role of Cytotoxicity and Growth Inhibition
Chaudhary, P., Srivastava, P., & Manna, P. P. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2908293 · Cited by 7 · see citing works
Adeno‐associated viral vector gene therapy: Challenges for the paediatric hepatologist
Jagadisan, B., & Dhawan, A. K. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12326 · Cited by 7 · see citing works
AAV Immunogenicity: New Answers Create New Questions
Shirley, J. L., & Herzog, R. W. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.004 · Cited by 7 · see citing works
Self-citationHuman tonsil organoids reveal innate pathways modulating humoral and cellular responses to ChAdOx1
Pudjohartono, M. F., Powell, K., Barnes, E. J., Klenerman, P., & Provine, N. M. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013432 · Cited by 6 · see citing works
Current perspective on biological properties of plasmacytoid dendritic cells and dysfunction in gut
Guo, X., He, C.-W., Xin, S.-Z., Gao, H., Wang, B.-Y., Liu, X.-H., Zhang, S.-T., Gong, F., Yu, X., Pan, L.-M., et al. (2023) · Immunity, Inflammation and Disease · doi:10.1002/iid3.1005 · Cited by 5 · see citing works
Abdelhamid, L., & Mazor, R. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01127-5 · Cited by 6 · see citing works
Organoid transduction using recombinant adeno‐associated viral vectors: Challenges and opportunities
Belova, L., Лавров, А. В., & Smirnikhina, S. (2022) · BioEssays · doi:10.1002/bies.202200055 · Cited by 5 · see citing works
Masri, S., Carré, L., Jaulin, N., Vandamme, C., Couzinié, C., Guy‐Duché, A., Dupont, J.-B., Pereira, A., Charpentier, É., David, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310447 · Cited by 5 · see citing works
Safety of in vivo gene therapy in children: mechanisms and management of liver injury
Jeyaraj, R., Brown, L. K., Jagadisan, B., Francesco Muntoni, A., Baruteau, J., Gupte, G. L., Breuer, J., Gissen, P., Oo, Y. H., & Dhawan, A. K. (2026) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(25)00380-3 · Cited by 4 · see citing works
Gao, C., Zhuang, X., Zhang, L., Li, M., Li, J. J., Li, J. B., & Zhu, Q. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.10.090 · Cited by 4 · see citing works
Pathogenetic value of cell infiltrate in immunoinflammatory rheumatic diseases
Зиявдинович, С. М. (2021) · Medical Immunology (Russia) · doi:10.15789/1563-0625-pvo-2386 · Cited by 4 · see citing works
- Authors
- Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., Terhorst, C., Biswas, M., & Herzog, R. W.
- Affiliations
- University of Florida Health (US)
- Center of Molecular and Cellular Therapeutics, The Children’s Hospital of Philadelphia, Philadelphia, PA;
- University of Florida (US)
- Beth Israel Deaconess Medical Center (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-06-15
- Volume
- 129
- Issue
- 24
- Pages
- 3184-3195
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC5472899
- OpenAlex
- W2610861971
- Semantic Scholar
- e6cfb89e4d66a95c980f78792a7ed364f7e69294
- Cited by
- 131
- References
- 60
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 16 · 2023: 17 · 2022: 15 · 2021: 19 · 2020: 7 · 2019: 15 · 2018: 11 · 2017: 4
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL-097088, HL131093, R01HL097088, R01HL131093)
- National Institute of Allergy and Infectious Diseases (R01AI051390, R01 AI51390, T32AI007110)
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK104194)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- plasmacytoid dendritic cells, myeloid dendritic cells, cross-presentation, AAV capsid, CD8+ T cells, viral DNA sensing, innate immunity
- MeSH terms
- Dependovirus, Animals, Dendritic Cells, Lymphocyte Activation, Plasma Cells, Genetic Therapy, Mice, Knockout, CD8-Positive T-Lymphocytes, Capsid Proteins, Toll-Like Receptor 9, Mice, Myeloid Differentiation Factor 88
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
